AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial
Imfinzi, along with four cycles of standard-of-care (SoC) chemotherapy, showed a statistically-significant and clinically-meaningful improvement in OS against SoC including up to six cycles of chemotherapy and optional
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.